Stryker Corporation

New York Stock Exchange
Back to all articles
Bullish +75

Down 9% From All-Time High, Can Stryker Stock Deliver Further Returns in 2026? - TIKR.com

📈 Stryker delivered exceptional Q4 results with 11% organic sales growth, capping a year where revenues surpassed $25 billion.

🤖 The Mako robotic platform achieved record installations, expanding its global base to over 3,000 systems worldwide.

🏥 Over two-thirds of U.S. knee procedures and one-third of hip procedures are now performed using the Mako system.

📅 Management guides for 2026 organic growth between 8% and 9.5%, with a price target projection of $503 by December 2028.

🛠️ MedSurg instruments grew 19.1% organically in the U.S., driven by strong demand for power tools and capital equipment.

💰 Despite $400 million in tariff headwinds, adjusted operating margins expanded by 100 basis points for the second consecutive year.

🌍 International markets present strong growth potential as regulatory approvals catch up to U.S. launches for key products like Insignia hip stems.

🔧 The company maintains a robust balance sheet providing firepower for strategic M&A in 2026, following acquisitions like Vocera and Inari.

📉 Analysts project modest P/E compression from historical averages to 24.9x over the forecast period due to scale challenges.

🎯 High-case scenarios suggest returns could hit 87% total if robotic adoption exceeds expectations and margins are maintained.

Bullish Signals
  • Stryker achieved its fourth consecutive year of double-digit revenue expansion, with Q4 organic sales growth reaching 11%.
  • The Mako robotic platform is becoming the standard of care, with over two-thirds of U.S. knee procedures now performed robotically.
  • MedSurg instruments grew 19.1% organically in the U.S., demonstrating strong demand for power tools and capital equipment.
  • The company successfully expanded adjusted operating margins by 100 basis points despite facing $400 million in tariff headwinds.
  • Management targets at least 150 basis points of additional margin expansion through 2028 through operational excellence initiatives.
  • Stryker has a robust balance sheet that provides significant firepower for future M&A activity to drive growth.
  • International markets offer accelerated growth potential as products like Insignia hip stems gain regulatory approval in Europe.
Risk Factors
  • The company faces $400 million in tariff headwinds for the full year, which impacts overall profitability.
  • Maintaining double-digit growth rates becomes inherently more difficult as the company scales to a larger size.
  • International expansion is currently delayed by regulatory approvals, particularly regarding EU MDR regulations for key products.
  • Analysts assume modest compression of the P/E multiple from historical averages due to the challenges of sustaining high growth at scale.
Full Analysis
Stryker Corporation (SYK) reported exceptional Q4 results with 11% organic sales growth, capping a year where revenues surpassed $25 billion for the first time. This marks the fourth consecutive year of double-digit expansion for the medical device giant. The company's standout performer was its Mako robotic platform, which saw record installations in Q4, expanding its global installed base to over 3,000 systems. Consequently, two-thirds of U.S. knee procedures and one-third of hip procedures are now performed using the Mako system. Management maintains a robust outlook with 2026 organic growth guidance set between 8% and 9.5%. CEO Kevin Lobo highlighted structural drivers including exceptional talent, active M&A activity, a steady cadence of product launches, and systematic specialization through new business units. The MedSurg segment also delivered impressive results, with instruments growing 19.1% organically in the U.S. driven by demand for power tools and capital equipment, while endoscopy grew 11.1%. Despite facing $400 million in tariff headwinds for the full year, Stryker expanded adjusted operating margins by 100 basis points for the second consecutive year, demonstrating strong operational efficiency. The company projects a total return of 30% to reach a price target of $503 by December 2028, implying roughly 9.7% annual growth over the next 2.8 years. Analysts view Stryker as benefiting from structural tailwinds in robotic surgery adoption and a diversified portfolio that allows for continued margin expansion even as it absorbs external cost pressures.